Your search for non small cell lung cancer returned 92 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Older than 2 years remove
Drugs in the Pipeline remove

Your search for non small cell lung cancer returned 92 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

PARP Inhibitor Veliparib Gets Orphan Drug Status from FDA

AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an investigational combination with chemotherapies or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline

Positive Outcomes Observed with Xalkori in NSCLC Study

Pfizer announced results from PROFILE 1014, a Phase 3 study of Xalkori (crizotinib) in previously untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline

AbbVie Launches Veliparib Trial for NSCLC

AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib (ABT-888) in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline

Phase 3 Trial Update of Alimta for Nonsquamous Non-Small Cell Lung Cancer

Eli Lilly and Company announced today that the Phase 3 POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of Alimta (pemetrexed for injection) with bevacizumab (Avastin; Genentech) and carboplatin induction followed by Alimta plus bevacizumab maintenance-the Alimta arm-compared to the combination of paclitaxel (Taxol; Bristol-Myers Squibb) with bevacizumab and carboplatin followed by bevacizumab maintenance-the paclitaxel arm.
Drugs in the Pipeline

Retaspimycin HCl Falls Short in NSCLC Trial

Phase 2 results announced for retaspimycin HCl (Infinity Pharmaceuticals) in combination with docetaxel in patients with non-small cell lung cancer (NSCLC) who had a history of smoking.